Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

Dear Common Dreams Readers:
Corporations and billionaires have their own media. Shouldn't we? When you “follow the money” that funds our independent journalism, it all leads back to this: people like you. Our supporters are what allows us to produce journalism in the public interest that is beholden only to people, our planet, and the common good. Please support our Mid-Year Campaign so that we always have a newsroom for the people that is funded by the people. Thank you for your support. --Jon Queally, managing editor

Join the small group of generous readers who donate, keeping Common Dreams free for millions of people each year. Without your help, we won’t survive.

People receive coronavirus vaccines in Mumbai, India

People receive coronavirus vaccines at a hospital in Mumbai, India on September 29, 2021. (Photo: Vijay Bate/Hindustan Times via Getty Images)

Unpatented Shot Dubbed 'The World's Covid-19 Vaccine' Wins Emergency Approval in India

"This announcement is an important first step in vaccinating the world and halting the pandemic," said Dr. Peter Hotez, a U.S.-based vaccine scientist.

Jake Johnson

An unpatented Covid-19 vaccine developed by the Texas Children's Hospital, Baylor College of Medicine, and the pharmaceutical firm Biological E. Limited received emergency-use authorization from Indian regulators on Tuesday—news that the jab's creators hailed as a potential turning point in the push to broaden global vaccine access.

"Our Texas Children's Center does not plan to make money on this, it's a gift to the world."

"This announcement is an important first step in vaccinating the world and halting the pandemic," Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor and co-director of the Texas Children's Hospital Center for Vaccine Development, said in a statement.

Formally known as Corbevax, the protein-based vaccine has been nicknamed "The World's Covid-19 Vaccine" because it is not patented, meaning that manufacturers across the globe can produce the shot without fear of legal retribution from governments or private companies.

"This vaccine can be made locally all over the world, and we've now technology-transferred our Texas Children's vaccine to producers in India, Indonesia, Bangladesh, [and] Botswana," Hotez wrote on Twitter. "Our Texas Children's Center does not plan to make money on this, it's a gift to the world."

The approach Corbevax's developers have opted to pursue stands in stark contrast to that of Pfizer and Moderna, U.S.-based pharmaceutical giants that are fiercely guarding their vaccine recipes—and reaping massive profits—as billions of people in low-income countries remain without access to the lifesaving shots nearly two years into the deadly pandemic.

According to new figures from the healthcare data firm Airfinity, poor countries have received fewer than 2% of all coronavirus vaccine doses distributed worldwide.

Dr. Maria Elena Bottazzi, associate dean of the National School of Tropical Medicine at Baylor and co-director of the Texas Children's Hospital Center for Vaccine Development, said Tuesday that "protein-based vaccines have been widely used to prevent many other diseases, have proven safety records, and use economies of scale to achieve low-cost scalability across the world."

"Our decade-long studies advancing coronavirus vaccine prototypes has led to the creation of this vaccine, which will fill the access gap created by the more expensive, newer vaccine technologies and that today are still not able to be quickly scaled for global production."

In a press release issued Tuesday, the Hyderabad, India-based company Biological E. Limited (BE) said Corbevax was "found to be safe, well-tolerated, and immunogenic" in two Phase III clinical trials involving more than 3,000 subjects between the ages of 18 and 80 at dozens of study sites across India.

Specifically, the company said Corbevax demonstrated a superior immune response compared to the Oxford/AstraZeneca vaccine—also known as Covishield—against both the original coronavirus strain and the still-pervasive Delta variant.

BE announced Tuesday that it intends to produce more than 100 million Corbevax doses per month starting in February 2022 and pledged to distribute over a billion doses globally in the coming months as nations grapple with surging cases.

"Over the years, we have worked to make quality vaccines and pharmaceutical products accessible to families around the world. With this as our backdrop, we resolved to develop an affordable and effective Covid-19 vaccine," Mahima Datla, BE's managing director, said in a statement. "It has now become a reality."

The makers of Corbevax didn't specifically say whether the shot is effective against the heavily mutated Omicron strain, which is quickly becoming dominant in countries across the globe. But Hotez argued that "widespread and global vaccination with our Texas Children's-Baylor-BE vaccine would also forestall the emergence of new variants."

"Our scientists at Texas Children's Hospital and Baylor College of Medicine are thrilled to help in the development of this vaccine, possibly the first Covid vaccine specifically designed for global health," said Hotez.


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

"I'm sure this will be all over the corporate media, right?"
That’s what one longtime Common Dreams reader said yesterday after the newsroom reported on new research showing how corporate price gouging surged to a nearly 70-year high in 2021. While major broadcasters, newspapers, and other outlets continue to carry water for their corporate advertisers when they report on issues like inflation, economic inequality, and the climate emergency, our independence empowers us to provide you stories and perspectives that powerful interests don’t want you to have. But this independence is only possible because of support from readers like you. You make the difference. If our support dries up, so will we. Our crucial Mid-Year Campaign is now underway and we are in emergency mode to make sure we raise the necessary funds so that every day we can bring you the stories that corporate, for-profit outlets ignore and neglect. Please, if you can, support Common Dreams today.

 

Abortion Rights Defenders Applaud Judge's Block on Utah 'Trigger Ban'

"Today is a win, but it is only the first step in what will undoubtedly be a long and difficult fight," said one pro-choice advocate.

Brett Wilkins ·


Scores Feared Dead and Wounded as Russian Missiles Hit Ukraine Shopping Center

"People just burned alive," said Ukraine's interior minister, while the head of the Poltava region stated that "it is too early to talk about the final number of the killed."

Brett Wilkins ·


Biodiversity Risks Could Persist for Decades After Global Temperature Peak

One study co-author said the findings "should act as a wake-up call that delaying emissions cuts will mean a temperature overshoot that comes at an astronomical cost to nature and humans that unproven negative emission technologies cannot simply reverse."

Jessica Corbett ·


Amnesty Report Demands Biden Take Action to End Death Penalty

"The world is waiting for the USA to do what almost 100 countries have achieved during this past half-century—total abolition of the death penalty," said the group.

Julia Conley ·


Pointing to 'Recently Obtained Evidence,' Jan. 6 Panel Calls Surprise Tuesday Hearing

The announcement came less than a week after the House panel delayed new hearings until next month, citing a "deluge" of fresh evidence.

Common Dreams staff ·

Common Dreams Logo